New Issue of PxWire!

PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Each issue includes news, emerging issues and features upcoming events.

The HIV field gathers for its first hybrid International AIDS Conference (IAC) since the start of COVID-19 pandemic at a pivotal moment in HIV prevention. Across research to rollout – accelerated product access, new products reaching the market, new trials starting (and pausing) and recent research results – the ability to deliver two new proven PrEP methods will be determined by conversations and decisions happening now.

After initial approval ten years ago, oral PrEP initiations have surpassed 2M globally, reaching 2,797,304 – with significant progress over the past year, but still well below UN targets.

Check out the full issue of PxWire here and scroll down for important updates.

phases in trial development

bar chart of PrEP uptake worldwide

preparing for new products dashboard

updates on products upstream in clinical trials

Message from Montreal: Which way will we go?

A string of announcements today coming from AIDS 2022 mark a potential turning point for HIV prevention and for the global health field at large, but a grave question hangs in the balance: which way will we go?

The big news yesterday was a dire warning: the launch of the UNAIDS report, In Danger, documenting what HIV advocates have known: that during the earliest phases of the COVID-19 pandemic, progress against HIV did not just stall, it actively lost ground.

The news today included: promising developments with new data from the HPTN 083 and 084 trials testing injectable cabotegravir for PrEP, which re-confirmed its safety and efficacy; WHO announced new guidelines adding injectable PrEP as an additional prevention option; the drug-maker for the first approved product of injectable PrEP (cabotegravir as PrEP), ViiV, announced an agreement with the Medicines Patent Pool to provide a voluntary license and begin the process of identifying generic manufacturers; and a new coalition was announced, convened by Unitaid, WHO, UNAIDS and the Global Fund, with AVAC serving as the secretariat, to collaborate with civil society, normative agencies, governments, and funders, in accelerating access to affordable longer-acting PrEP.

In the whiplash of announcements and headlines, it’s vital to understand how much is at stake at this moment.

Will proven biomedical options become feasible choices for people who need and want them? Will policies, programs and investments come together for equitable access? It’s up to all of us.

PrEP has an important role to play in reaching targets and accelerating an end to the epidemic. But new AVAC data show only around 2.7 million people have initiated use of oral PrEP since it was introduced ten years ago, falling short of the 2020 target of three million users – and representing only a fraction of the estimated number of people who need it and could benefit from it. Now, the dapivirine vaginal ring and injectable cabotegravir (CAB for PrEP) offer additional options – and an opportunity to re-imagine HIV prevention.

The news from Montreal show promise and potential to develop and deliver new PrEP options faster, smarter and with greater equity than ever before.

AVAC’s Plan for Accelerating Access and Introduction of Injectable CAB for PrEP provides a comprehensive view of all the moving parts involved in delivering this new PrEP option and identifies priorities for ensuring time is not wasted and opportunity is not squandered. The plan focuses on learning the lessons from the first ten years of delivering oral PrEP. It shows how to move faster, more strategically, and with greater coordination— to maximize the impact of injectable CAB for PrEP today, and to overcome access challenges for new PrEP options in the future.

thumbnail of the CAB plan

There is enormous work ahead, and it will require all proven prevention methods be available in a marketplace of choice. And these efforts must integrate the involvement of all stakeholders, including civil society, to hold each other accountable. We encourage you to read the plan, or our summary of it, and follow events in real time on Twitter at #AIDS2022. And learn more about the dapivirine vaginal ring and injectable cabotegravir (CAB for PrEP).

African Activists Call for Women and Girls to have a Voice in HIV Prevention Choices

African feminists and HIV prevention advocates are united in their advocacy for ensuring African women and girls in their diversity have a range of HIV prevention options to choose from, including the dapivirine vaginal ring.

While several African countries have approved the licensure of the ring and the WHO has included the ring on the list of essential medicines, some donors are backing away from their support of the ring for rollout beyond the planned Introductory studies as well as support for future research in longer acting rings. Advocates have called for accelerated access to the ring and not to lose sight of the importance of championing choice and respecting the investment African women and communities have made in bringing the ring to this point.

Read more and see the signatories to the statement on the WACI Health website.

AIDS 2022 Montreal Coming Up!

AIDS 2022 logo

The world’s largest conference on HIV/AIDS, AIDS 2022, convenes July 27-August 2 in Montreal, Canada. Hosted by the International AIDS Society, this 24th session of the conference will be the first since the pandemic to offer in-person and virtual access. Register for the full conference here and the pre-conference here.

AIDS 2022 launches at a pivotal moment in HIV prevention. The ability to deliver two new proven PrEP methods will be determined by conversations and decisions happening now. These decisions will impact policies and funding for products in the pipeline and programs to deliver what’s available today for HIV prevention. It’s time to sharpen the agenda for HIV prevention and global health equity. AIDS 2022 will offer opportunities to engage in these conversations while getting up to date on the latest research, rollout, policy and advocacy.

Below AVAC has gathered resources to help you navigate the conference overall and find the sessions on prevention that we hope will interest you, keep you informed, and support conversations that will shape the future of the global response to HIV.


Panels, Satellites, Sessions and Workshops Featuring AVAC and Partners

Friday, July 29

  • [Satellite] Next Generation PrEP: Science, policy, and community impact
    18:15-19:45 EDT

    How do clinical trials assess efficacy of new and still-needed experimental products, with highly effective options available to the public? This session explores the need to bring key stakeholders including communities, industry and regulators to questions such as: How do regulators approach groundbreaking new trial designs in HIV prevention? How do these trial designs affect patients in the trials and those that may benefit from candidate drugs?

Saturday, July 30

  • [Symposium] Equitable roll out of health products: What will it take?
    14:15-15:15 EDT

    Discussing innovative strategies, collaborative partnerships and transparent processes that engage advocates, government agencies, policy makers, government and non-governmental funders, regulatory bodies and pharmaceutical companies and result in equitable access to new products, the key to achieving rapid and effective product rollout.

Sunday, July 31

flyer for our next shot workshop

flyer for demand, delivery and data for decision-making meeting

Monday, August 1

Find these resources, conference highlights and more at AVAC’s dedicated AIDS 2022 event page. And watch this space for new opportunities to come together and shape what happens next.

It’s All About Choice

Real choices in healthcare are fundamental. They empower individuals, advance equity across healthcare systems and transcend healthcare altogether, fostering community resilience. But choice depends on commitment, requires investment and needs champions.

At AVAC, we are thinking intensely about how to be a champion for choice. Wherever our work takes us. Here’s what’s top of mind today.

Our newly launched initiative, The Choice Agenda (TCA), led by veteran advocate Jim Pickett, is hosting its next webinar in its series on HIV prevention, The Research Says Yes, YES, YES – Just Like That, Wednesday, July 13 at 9:00am ET / 1:00pm GMT / 15:00 SAST. Register now.

This webinar explores insights from HIV prevention and sexual health research that point to the many positive outcomes when we center and prioritize pleasure and sexual satisfaction in our interventions and prevention programming.

We’ll be featuring a discussion with experts:

• Christine M. Curley, University of Connecticut

• Dr. Joao Alves Neto, University of Minho (Portugal) and FACEFI (Brazil)

• Anne Philpott, The Pleasure Project

Get access to our previous webinars, register for what’s upcoming on The Choice Agenda webpage, and sign up with to join the TCA listserve for dynamic, cross-cutting conversations with hundreds of dedicated advocates.

Fighting for Choice Together

All of our voices must be heard to protect and expand access to real choices for everyone who needs them. Especially when it comes to sexual health, which is so often stigmatized and often profoundly under threat. AVAC condemns last month’s decision by the US Supreme Court, which rolls back decades of protections for those seeking safe abortion services in the US and undermines other landmark rulings that safeguard fundamental human rights, privacy and personal liberty.

Read AVAC’s statementRead AVAC’s statement condemning the opinion and declaring our commitment to stand always for reproductive justice and to work with our partners and allies to ensure that the right to abortion is protected.